Thomas Powles, Jonathan E. Rosenberg, Shilpa Gupta, Yohann Loriot, Marc-Oliver Grimm, Julius Strauss, Arnold Bruce Gelb, Sean E. McLean, Luoying Yang, Maurice Lobo, David Perez Callejo, Jimmy L. Zhao, Jonathan D. Cheng, Matthew D. Galsky. "IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.7_suppl.tps883